ClinicalTrials.gg
CompletedNCT03404115Updated Feb 6, 2025Results posted

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Reproxalap Ophthalmic Solution (0.1%) in Dry Eye Syndrome, sponsored by Aldeyra Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
5th of 11
300 · median 158
Started
2018
the only one that year
Phase 2
5 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 2, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry Eye Disease

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

Keywords

  • reproxalap
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age of either gender and any race;
  • Have a reported history of dry eye for at least 6 months prior to Visit 1;
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;

Exclusion criteria

Exclusion Criteria:

  • Have any slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have used any eye drops within 2 hours of Visit 1;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 90 days of Visit 1;
  • Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
  • Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%)

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Experimental
    Reproxalap Ophthalmic Solution (0.1%)

    Drug: Reproxalap Ophthalmic Solution (0.1%)

  • Placebo comparator
    Vehicle Ophthalmic Solution

    Drug: Vehicle Ophthalmic Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness.

    Change from baseline comparison of ADX-102 to Vehicle on the Ora Calibra® Discomfort \& 4-Symptom Questionnaire (0 = least, 5 = most) for dryness across all time points. The intervention was administered bilaterally. The Least Squares Mean (Standard Error) was derived from Mixed Model Repeated Measure for change from baseline calculated using baseline score, visit, treatment, and visit-by-treatment interaction.

    Time frame: Efficacy assessment period (Day 1 through Day 85) - assessed on Days 1, 15, 29, 57, and 85.

07

Results

Posted Feb 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneReproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic Solution
Started100100100
Completed978899
Not completed3121

Outcome measures

PrimaryEfficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness.

Change from baseline comparison of ADX-102 to Vehicle on the Ora Calibra® Discomfort \& 4-Symptom Questionnaire (0 = least, 5 = most) for dryness across all time points. The intervention was administered bilaterally. The Least Squares Mean (Standard Error) was derived from Mixed Model Repeated Measure for change from baseline calculated using baseline score, visit, treatment, and visit-by-treatment interaction.

Time frame:
Efficacy assessment period (Day 1 through Day 85) - assessed on Days 1, 15, 29, 57, and 85.
Reported as:
Least squares mean · units on a scale
Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness.
units on a scaleReproxalap (0.25%)Reproxalap (0.1%)Vehicle
Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness.-0.7 ± 0.09-0.5 ± 0.08-0.4 ± 0.08

Adverse events

Collected over The period of time when adverse events were collected was approximately 3 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap Ophthalmic Solution (0.25%)0/100 (0%)1/100 (1%)93/100 (93%)
Reproxalap Ophthalmic Solution (0.1%)0/100 (0%)1/100 (1%)37/100 (37%)
Vehicle Ophthalmic Solution0/100 (0%)0/100 (0%)2/100 (2%)
Most frequent serious events
Most frequent serious events
EventReproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic Solution
Angina pectorisCardiac disorders1/1000/1000/100
VertigoEar and labyrinth disorders0/1001/1000/100
Most frequent other events
Most frequent other events
EventReproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic Solution
General disorders and administration site conditionsGeneral disorders93/10037/1002/100

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
<=18 years0000
Between 18 and 65 years585051159
>=65 years425049141
Sex: Female, Male
Sex: Female, Male(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
Female757628179
Male252472121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
Hispanic or Latino2417
Not Hispanic or Latino989699293
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
American Indian or Alaska Native0011
Asian1214
Native Hawaiian or Other Pacific Islander0000
Black or African American22171756
White778080237
More than one race0101
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
United States100100100300
Iris Color (Right Eye)
Iris Color (Right Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
Black1124
Blue15222663
Brown554746148
Green7111028
Hazel22171655
Gray0202
Other0000
Iris Color (Left Eye)
Iris Color (Left Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%)Reproxalap Ophthalmic Solution (0.1%)Vehicle Ophthalmic SolutionTotal
Black1124
Blue15222663
Brown554746148
Green7111028
Hazel22171655
Gray0202
Other0000
08

Study locations

6 sites
  • The Eye Care Group
    Waterbury, Connecticut 06708, United States
  • Midwest Cornea Associates
    Indianapolis, Indiana 46290, United States
  • Central Maine Eye Care
    Lewiston, Maine 04240, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • Andover Eye Associates
    Raynham, Massachusetts 02767, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
09

References and documents

Publications

  • Clark D, Sheppard J, Brady TC. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. J Ocul Pharmacol Ther. 2021 May;37(4):193-199. doi: 10.1089/jop.2020.0087. Epub 2021 Jan 15. PubMed 33450164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2018, 6 months.

Results were first posted in Feb 2025, 6 years 6 months after primary completion. A results delay was requested in Jul 2019.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 6 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 19, 2018
StartActual
Jan 2, 2018
Primary completionActual
Jul 11, 2018
CompletionActual
Jul 11, 2018
Results delay requested
Jul 10, 2019
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03404115
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Jan 2, 2018
Primary completion
Jul 11, 2018
Completion
Jul 11, 2018
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion